Urology
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
To estimate and compare recurrence rates, index of recurrence, and disease-free interval in patients with superficial recurrent bladder cancer receiving bacille Calmette-Guérin (BCG) or interferon (IFN) for immunoprophylaxis. ⋯ According to our trial, BCG remains the most efficacious agent for immunoprophylaxis of recurrent superficial bladder tumors.